Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: GDRX stock price vs ROIV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROIV's multiple
Needs ROIV P/E.
Implied fair value · at GDRX's multiple
Needs Annual EPS is negative, GDRX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GoodRx Holdings, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Evolent Health, Inc.
GDRX vs EVH
CVS HEALTH Corp
GDRX vs CVS
Doximity, Inc.
GDRX vs DOCS
Criteo S.A.
GDRX vs CRTO
Revolution Medicines, Inc.
GDRX vs RVMD
INCYTE CORP
GDRX vs INCY
Sarepta Therapeutics, Inc.
GDRX vs SRPT
EXELIXIS, INC.
GDRX vs EXEL
VERTEX PHARMACEUTICALS INC / MA
GDRX vs VRTX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe GDRX should be valued on its positive earnings and revenue-generating profile rather than ROIV's highly distorted multiples, then GDRX looks like the better buy because its current $2.65 price is below the DCF range and near the bottom of its historical band while fundamentals are materially stronger.
The valuation gap is extreme: GDRX trades at 1.2x P/S and 1.5x EV/Revenue versus ROIV at 2639.4x P/S and 2173.3x EV/Revenue, which mathematically drives ROIV-implied price to an unrealistic $5902.39. GDRX is instead anchored by its historical band of $2.38 to $2.92 and DCF range of $3.44 to $4.65, putting the current $2.65 price near the low end of historical valuation and below DCF.
Supporting Metrics
